1 / 13

Pediatrics Update

Pediatrics Update. Dianne Murphy, M.D. Director, Office of Pediatric Therapeutics Office of the Commissioner Director, OCTAP Center for Drug Evaluation March 3, 2003. Pediatrics Update. Organization of Pediatrics - D. Murphy New Office of Pediatric Therapeutics - D. Murphy

ellery
Download Presentation

Pediatrics Update

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pediatrics Update Dianne Murphy, M.D. Director, Office of Pediatric Therapeutics Office of the Commissioner Director, OCTAP Center for Drug Evaluation March 3, 2003

  2. Pediatrics Update • Organization of Pediatrics - D. Murphy • New Office of Pediatric Therapeutics - D. Murphy • Overview of Postmarketing Safety Surveillance in FDA – M. Chen • Adverse Events Reporting - S. Iyasu • Division of Pediatric Drug Development - S. Murphy • Statistics - T. Crescenzi

  3. Historical Perspective Office of Pediatric Drug Development and Program Initiatives (OPDDPI) Office of Counter-Terrorism & Pediatric Drug Development (OCTAP) Division of Pediatric Drug Division of Counter-Terrorism Development (DCT) (DPDD)

  4. Pediatrics Structure Office of the FDA Commissioner International Activities & Strategic Initiatives CDER Office of Pediatric Therapeutics OCTAP Division of Pediatric Drug Development

  5. Office of Pediatric Therapeutics • How established? • Best Pharmaceuticals for Children Act (1/4/02) • Section 6 • Duties? • “Coordination and facilitation of all activities of FDA that may have any effect on a pediatric population OR • the practice of pediatrics OR • may in any way involve pediatric issues”

  6. Office of Pediatric Therapeutics Staff: • One or more individuals with expertise concerning ethical issues • position currently being advertised in NEJM • One or more experts in Pediatrics • Solomon Iyasu, M.D., M.P.H. • adverse event reporting

  7. Office of Pediatric Therapeutics Two important functions that impact you • Subpart D • Adverse Event Reporting

  8. Office of Pediatric Therapeutics Subpart D • FDA regulated products • Expert panel to be convened because of referral from an IRB

  9. Office of Pediatric Therapeutics Adverse Event Reporting • Drugs with Pediatric Market Exclusivity • Any adverse event reports must be referred to the Office of Pediatric Therapeutics for a one-year period from the date a drug receives pediatric exclusivity. • Review of reports by Pediatric Advisory Subcommittee

  10. Office of Pediatric Therapeutics Adverse Event Reporting • Partnership between Office of Drug Safety (ODS) and Office of Pediatric Therapeutics (OPT) • ODS - How they collect adverse events • OPT - Solomon Iyasu, M.D., M.P.H. • How we will report adverse events to you

  11. Office of Pediatric Therapeutics • How to avoid overlap and duplication with Division of Pediatric Drug Development? • Solution = Efficiencies

  12. Efficiencies

  13. Office of Pediatric Therapeutics How to Contact Us? Email: opt@fda.gov Phone: 301-827-9218 Fax: 301-827-4001

More Related